eyeforpharma Barcelona 2018

eyeforpharma13 - 15 March 2018, Barcelona, Spain.
eyeforpharma Barcelona is an annual pilgrimage for pharma's executives who want to map their future commercial success. Now it has become the place to map a different journey, that of our customers and patients. Gain their trust and serve as their guiding light towards better outcomes for all.

One eyeforpharma Barcelona. 9 in-depth commercial pharma conferences on the key issues of 2018 and beyond. This year we will bring you unrivalled expertise, patient insights, real-world data - the building blocks to deliver innovative and complete healthcare solutions, to make a real difference to the lives of patients and customers.

1. A Vision for the Future
2. Commercial Model Innovation
3. Talent and Diversity
4. Patient Partnerships
5. Advances in Customer Engagement
6. Digital Innovation and Analytics
7. Sales Force Effectiveness
8. Interactive Sessions - you lead the discussion
9. Medical Affairs

Why you can't miss Barcelona 2018

Barcelona is not a normal conference. Our mission is to create the mass movement we need across the pharma industry.

We must ask ourselves is it possible for a pharma company to be a credible, go-to source of health knowledge? Is it possible to be trusted, respected and admired? Despite having all the resources, expertise and reach, pharmaceutical companies are still a long way from this. To get there, each company must better appreciate the value it provides - and to have a greater vision for the value it can provide.

2018 will guarantee:

  • Collaborative setting: Our aim to ensure your key stakeholder are present to advance partnerships with healthcare, technology, patient and patient association
  • An Inspiring Agenda: As you undergo a commercial evolution we will cover 9 themes, provide intimate workshops and keynote sessions to help direct your journey
  • 1200+ in attendance: If you are looking for one commercial meeting to attend in 2018, Barcelona will be sure to give you the most senior networking opportunities possible
  • NO Sales Pitch: this is an independently researched event committed to equipping you with the techniques and expertise to drive your business. You will take-away actionable insights proven to drive your commercial strategy
  • More Than 80 Executive-level Thought Leaders sharing their experience and knowledge. Take this opportunity to transform your organisation, become truly customer-centric and improve healthcare outcomes.

Join the most forward-thinking speakers from across Europe including C-Level, VPs and Industry leaders from J&J, Bayer Pharmaceuticals, Lilly Bio Medicines, Teva, Takeda and MSD. This is the ideal place to ensure your commercial strategy is prepared for 2018 and beyond.

World Pharma News readers can benefit from an exclusive discount - save €200 using the unique discount code WPN200 when you register online here.

For further information, please visit:
http://www.eyeforpharma.com/barcelona/

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the centre.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Roche's first FDA-approved tumour-agnostic medicin…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with R...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...